Predictive Oncology Reports Year End 2023 Financial Results and Provides Business Update
- Company to host investor call and webcast on Monday, April 1st, at 8:30am EDT Company to host investor call and webcast on Monday, April 1st, at 8:30am EDT
- 03/28/2024
|
Predictive Oncology to Participate in Upcoming Investor Conferences
- PITTSBURGH, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, today announced that Raymond F. Vennare, Chief Executive Officer, will participate in three upcoming investor conferences. Please see below for additional details about the events and how to request a one-on-one meeting with management.
- 02/21/2024
|
3 Penny Stocks That Will Be the Surefire AI Winners of Tomorrow
- Artificial intelligence and penny stocks don't necessarily go together like peanut butter and jelly, but there is some allure to AI penny stocks for risk-tolerant investors. In 2023, companies were bending over backward to announce their AI bona fides.
- 01/18/2024
|
Predictive Oncology to Participate in Upcoming San Francisco Conferences
- PITTSBURGH, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, today announced that Raymond F. Vennare, Chief Executive Officer, will present at the upcoming Biotech Showcase, in San Francisco, CA, on January 9, 2024, at 4:00 p.m. PT. Company management will also participate in the 13th Annual LifeSci Partners Corporate Access Event and BIO Partnering @ JPM Week 2024. Please see below for additional details about the events and how to request a one-on-one meeting with management.
- 01/02/2024
|
Predictive Oncology Inc. (POAI) Q3 2023 Earnings Call Transcript
- Predictive Oncology Inc. (NASDAQ:POAI ) Q3 2023 Earnings Conference Call November 14, 2023 8:30 AM ET Company Participants Glenn Garmont - IR Raymond Vennare - CEO and Chairman Josh Blacher - CFO Conference Call Participants Operator Good day, and thank you for standing by. Welcome to the Predictive Oncology Q3 2023 Earnings Conference Call.
- 11/14/2023
|
Predictive Oncology 'pleased with progress' as it delivers 3Q results
- Predictive Oncology Inc. (NASDAQ:POAI) listed a number of recent milestones with the release of its third-quarter results, which also revealed a significant 22% reduction in its net loss. Chairman and CEO Raymond Vennare highlighted the delivery of successful results from its first campaign with Cancer Research Horizons, a subsidiary of the largest independent funder of cancer research in the world.
- 11/14/2023
|
Predictive Oncology Reports Third Quarter 2023 Financial Results and Provides Business Update
- Company to host investor call and webcast today, November 14th, at 8:30am EDT Company to host investor call and webcast today, November 14th, at 8:30am EDT
- 11/14/2023
|
Predictive Oncology completes AI-driven cancer study with UPMC Magee-Womens Hospital
- Predictive Oncology Inc announced that it has completed a multi-year study with UPMC Magee-Womens Hospital in Pittsburgh. The science-driven company said the objective of the study was to evaluate the use of AI to build multi-omic machine learning (ML) models and test if these models can learn associations between the datasets and ovarian cancer patient short- and long-term survival.
- 11/08/2023
|
Predictive Oncology Completes AI-driven Study of Ovarian Cancer with UPMC Magee-Womens Hospital
- PITTSBURGH, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, announced today that it has completed a multi-year study with UPMC Magee-Womens Hospital. The objective of the study was to evaluate the use of AI to build multi-omic machine learning (ML) models and test if these models can learn associations between the datasets and ovarian cancer patient short- and long-term survival.
- 11/08/2023
|
3 AI Stocks Worth Buying Now for Multibagger Returns
- With artificial intelligence (AI) showing no signs of cooling, we could see a $1.8 billion opportunity by 2030. AI is expected to help students learn better and faster, already profoundly impacting the medical industry and accelerating drug discovery.
- 10/10/2023
|
3 AI Stocks to Buy That Aren't on Your Radar
- Artificial intelligence is here to stay, and as FOMO sets in, investors are flocking to little-known AI stocks. However, that doesn't mean investors aren't becoming weary and even skeptical about the way different companies are touting their use of AI.
- 08/16/2023
|
Predictive Oncology, Inc. (POAI) Q2 2023 Earnings Call Transcript
- Predictive Oncology, Inc. (NASDAQ:POAI ) Q2 2023 Earnings Conference Call August 10, 2023 5:30 PM ET Company Participants Glenn Garmont - Managing Director at LifeSci Partners Raymond Vennare - Chief Executive Officer and Chairman of the Board Bob Myers - Chief Financial Officer Pamela Bush - Chief Business Officer Conference Call Participants Operator Good day, and thank you for standing by. Welcome to the Predictive Oncology Q2 2023 Earnings Conference Call.
- 08/10/2023
|
Predictive Oncology dramatically narrows its quarterly loss in latest financial results
- Predictive Oncology reported its second-quarter financial results after the bell Thursday, including a significantly narrower loss than the same quarter of 2022. The drug development company reported a loss of $0.98 per share, compared to $2.89 in the year-ago quarter.
- 08/10/2023
|
Predictive Oncology to Report Second Quarter 2023 Financial Results and Host Conference Call and Webcast on Thursday, August 10, 2023
- EAGAN, Minn., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (CLIA) laboratory and Good Manufacturing Practices (GMP) facility, to accelerate oncology drug discovery and enable drug development, today announced that it will report its financial results for the second quarter ended June 30, 2023 after the markets close on Thursday, August 10, 2023.
- 08/03/2023
|
3 AI Stocks to Buy Under $10 in August 2023
- The bull market in artificial intelligence is just getting started. In fact, with the boom only set to accelerate, we may be looking at a $1.81 trillion opportunity by 2030, says Grand View Research.
- 08/01/2023
|
7 AI Penny Stocks that Could Hit $5 Soon
- The era of artificial intelligence is upon us. By 2030, AI is expected to contribute $15.7 trillion to the global economy.
- 07/30/2023
|
Predictive Oncology moves company headquarters to Pittsburgh
- Predictive Oncology Inc. (NASDAQ:POAI) announced that it has moved its corporate headquarters to its main laboratory facility in Pittsburgh, Pennsylvania. The science-driven company said the logistical initiative further strengthens its commitment to scientific discovery and growth potential.
- 07/18/2023
|
Predictive Oncology adds biopharmaceutical CFO Andrew Einhorn to business advisory board
- Predictive Oncology Inc. (NASDAQ:POAI) has announced the addition of biopharmaceutical finance industry veteran Andrew Einhorn to its business advisory board. Einhorn is the chief financial officer at Danforth Advisors, where he helps build up life science companies using institutional knowledge and provides financial advisory services to public and privately held companies.
- 06/27/2023
|
Big Tech on the Prowl: 3 Potential AI Stock Acquisition Targets
- With the artificial intelligence boom gaining momentum, we're likely to see far more acquisitions for some of the top AI stocks to watch. For one, AI behemoths like Nvidia (NASDAQ: NVDA ), Alphabet (NASDAQ: GOOG , NASDAQ: GOOGL ), and Microsoft (NASDAQ: MSFT ) are exploring new ways to innovate, stay ultra-competitive, and ramp up revenue.
- 06/27/2023
|
Predictive Oncology appoints Dr Bernard Harris Jr to Business Advisory Board
- Predictive Oncology Inc. (NASDAQ:POAI) has announced the appointment of Dr Bernard Harris Jr to its newly-formed Business Advisory Board (BAB). The company said Harris, who previously worked at NASA, serves as CEO and managing partner of Vesalius Ventures, Inc, a venture capital firm that supports and invests in early-to-mid-stage healthcare companies.
- 06/20/2023
|
3 Penny Stocks That Have Game-Changing Technologies
- The NASDAQ index led the market out of technical bear market territory. And if the rally is going to have legs, investors will know they have artificial intelligence ( AI ) to thank for it.
- 06/13/2023
|
3 Pharma Stocks That Will Boom Thanks to AI
- A Deloitte report about artificial intelligence (AI) in the life sciences puts it bluntly. Big data is the new currency for biopharma firms.
- 05/26/2023
|
Predictive Oncology forges key partnerships to drive oncology drug development in 1Q
- Predictive Oncology has updated investors on its use of artificial intelligence (AI) and machine learning and its extensive biorepository of tumor samples, CLI laboratory and GMP facility to accelerate oncologic drug discovery and development during the first three months of 2023 along with the release of its first quarter financial results. Predictive Oncology CEO Raymond Vennare pointed to a number of milestones achieved during the quarter, including ground-breaking partnerships and key appointments.
- 05/16/2023
|
Predictive Oncology, Inc. (POAI) Q1 2023 Earnings Conference Call Transcript
- Predictive Oncology, Inc. (NASDAQ:POAI ) Q1 2023 Earnings Conference Call May 15, 2023 5:30 PM ET Company Participants Glenn Garmont - Managing Director at LifeSci Partners Raymond Vennare - Chief Executive Officer and Chairman of the Board Bob Myers - Chief Financial Officer Pamela Bush - Chief Business Officer Conference Call Participants Michael Broadbent - Private Investor Operator Good day, and thank you for standing by. Welcome to the Predictive Oncology Q1 2023 Earnings Conference Call.
- 05/15/2023
|
Predictive Oncology appoints healthcare commercial and business development veteran to its board
- Predictive Oncology Inc. (NASDAQ:POAI) said it has appointed healthcare commercial and business development veteran Dr Veena Rao to its board of directors. Dr Rao will replace David Smith, who is stepping down but will remain an advisor to the board and assume duties as legal counsel to the company.
- 05/03/2023
|
3 Undiscovered AI Stocks Set to Dominate the Market
- Artificial intelligence is one of the hottest stories of the year. Investors who believe in the technology, or who are simply looking to find growth wherever they can, are flocking into AI stocks.
- 05/03/2023
|
Penny Stocks To Buy? 10 Under $1 To Watch This Week
- Penny stocks under $1 to watch this week. The post Penny Stocks To Buy?
- 04/19/2023
|
Penny Stocks To Buy? 7 Under $1 To Watch This Week
- Penny stocks to watch trading for pennies this week. The post Penny Stocks To Buy?
- 04/17/2023
|
Predictive Oncology appoints translational research leader Christoph Reinhard to scientific advisory board
- Predictive Oncology Inc. (NASDAQ:POAI) announced the appointment of Dr. Christoph Reinhard to its scientific board to serve alongside other key thought leaders in their fields to guide the company's scientific initiatives and growth strategy.
- 04/04/2023
|
Predictive Oncology partners with Integra Therapeutics to advance gene therapy
- Predictive Oncology Inc. (NASDAQ:POAI) said it is partnering with Integra Therapeutics, a company focused on engineering the next generation of gene writing tools to cure diseases, to pursue a novel method to enhance Integra's ability to use gene editing for future cancer therapies. “Our novel formulation technology and protein expression experience positions Predictive Oncology to help advance Integra's goals,” said Larry DeLucas, Senior Vice President of Biologics at Predictive Oncology.
- 03/30/2023
|
Predictive Oncology, Inc. (POAI) Q4 2022 Earnings Conference Call Transcript
- Predictive Oncology, Inc. (NASDAQ:POAI ) Q4 2022 Earnings Conference Call March 22, 2023 12:00 PM ET Company Participants Theresa Ferguson - Senior Director of Marketing Raymond Vennare - Chief Executive Officer and Chairman of the Board Bob Myers - Chief Financial Officer Conference Call Participants Michael Broadbent - Bedrock Group, Inc. Danny Garcia - KSU Brenda Thompson - IBM Operator Good day and thank you for standing by. Welcome to the Predictive Oncology, Inc. Q4 2022 Earnings Conference Call.
- 03/22/2023
|
Predictive Oncology hails potential of PEDAL drug discovery platform as it reports 2022 results
- Predictive Oncology Inc. (NASDAQ:POAI) has highlighted the “untapped” potential of its PEDAL drug discovery platform alongside its results for the year ended December 31, 2022. “I assumed the role of chief executive officer of Predictive Oncology because, as a board member, I was able to see first-hand the untapped potential of the company's assets, notably its proprietary PEDAL drug discovery engine, which leverages our proprietary artificial intelligence and machine learning capabilities to facilitate more efficient oncologic drug discovery and enable drug development,” said Raymond F Vennare, chief executive officer and chairman of Predictive Oncology in the results statement.
- 03/22/2023
|
Predictive Oncology and Cancer Research Horizons partner up to pursue development of cancer drugs
- Predictive Oncology Inc. (NASDAQ:POAI) and Cancer Research Horizons, the innovation engine at the core of the world's largest private funder of cancer research, Cancer Research UK (CRUK), have announced a partnership to drive the development of oncology drugs utilizing Predictive Oncology's PEDAL platform. Minneapolis, Minnesota-based Predictive Oncology said the collaboration will utilize its PEDAL technology to evaluate Cancer Research Horizons' pre-clinical drug inhibitors of Glutaminase to determine which cancer types and patient populations are most likely to respond to treatment with these compounds.
- 03/17/2023
|
Predictive Oncology highlights successful restructuring and strategic partnerships in letter to shareholders
- Predictive Oncology Inc. (NASDAQ:POAI) CEO Raymond F Vennare told investors that the company is focusing on conducting transactions with biopharmaceutical partners and driving the adoption of its proprietary PEDAL drug discovery platform. “We have consolidated infrastructure, merged assets, reassigned personnel and gained domain expertise, thereby creating operational efficiencies and lowering overhead,” Vennare said in a letter to shareholders, “In the process of this consolidation and reassessment of all company assets and core competencies, we have identified currently existing opportunities which we believe will significantly broaden our intellectual property portfolio.
- 03/09/2023
|
Predictive Oncology and Cvergenx partner up to develop first-ever genomics-based AI approach to personalized radiation therapy and drug discovery
- Predictive Oncology Inc. (NASDAQ:POAI) and Cvergenx Inc forged an agreement to form a strategic partnership that has the potential to revolutionize the field of radiation oncology with the first-ever genomics-based artificial intelligence (AI) approach to personalized radiotherapy and drug discovery. Minneapolis, Minnesota-based Predictive Oncology, which has a unique approach to leveraging AI in oncology drug discovery, said the collaboration will leverage the combined power of both the firm's proprietary technologies and domain expertise for a common purpose.
- 02/23/2023
|
7 AI Penny Stocks That Could Skyrocket in 2023
- AI penny stocks provide investors with higher-risk, higher-upside exposure to companies specializing in developing or utilizing artificial intelligence technology. Since these stocks trade at a relatively low price per share and may be relatively unproven, operating in niche areas of the market, there's more to be gained by a correct bet on these stocks.
- 02/21/2023
|
Predictive Oncology launches ACE program to partner with academic and research institutions to advance drug discovery initiatives
- Predictive Oncology Inc. (NASDAQ:POAI) has announced the launch of ACE (Accelerating Compound Exploration), a program to advance oncology drug development initiatives with academic and research institutions. The Eagan, Minnesota-based company said it created ACE to grant early-stage academic drug development groups and technology transfer offices access to its PEDAL platform.
- 02/21/2023
|
4 ChatGPT Stocks To Watch In February Trading For Pennies
- ChatGPT AI Penny Stocks To Watch As Machine Learning Tech Heats Up The post 4 ChatGPT Stocks To Watch In February Trading For Pennies appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 02/08/2023
|
7 AI Penny Stocks to Watch as a New Bull Market Emerges
- Roughly a month into 2023, it's already clear that artificial intelligence (AI) is this year's first market boom. Since OpenAI launched ChatGPT, investors haven't been able to ignore the power of this new tech.
- 02/07/2023
|
Predictive Oncology appoints business development veteran Pamela Bush as chief business officer
- Predictive Oncology Inc. (NASDAQ:POAI) announced that it has appointed Pamela Bush as its chief business officer to lead all business development, partnering and growth strategies for the company. As a key member of the executive team, the company said Bush will spearhead its strategic, operational and financial planning initiatives for both existing customers and emerging new markets.
- 02/03/2023
|
Predictive Oncology adds Dr Robert F. Murphy to its scientific advisory board
- Predictive Oncology Inc. (NASDAQ:POAI) said it has appointed Dr Robert F. Murphy, a pioneer in the field of machine learning and analytics for biological data, to its scientific advisory board.
- 01/12/2023
|
7 Artificial Intelligence Stocks Under $10 for Your 2023 Watch List
- There is no denying that Artificial Intelligence (AI) will have a monumental impact on our lives in the upcoming decades. AI has the potential to completely revolutionize how we live and work, allowing us to make life easier and more rewarding for people all over the world.
- 01/11/2023
|
Predictive Oncology adds Chan Zuckerberg Initiative's Marc Malandro to its scientific advisory board
- Predictive Oncology Inc. (NASDAQ:POAI) has announced the appointment of Chan Zuckerberg Initiative executive Marc Malandro to its Scientific Advisory Board. The Eagan, Minnesota-based company called Malandro “a highly regarded scientific leader with significant experience in business, law and philanthropy.
- 12/13/2022
|
Predictive Oncology adds leading biopharma executive Dr Matthew J Hawryluk to its board
- Predictive Oncology Inc. (NASDAQ:POAI) has announced the appointment of Dr Matthew J Hawryluk to its board of directors in support of the company's strategic initiatives and commercialization efforts. With a PhD in cell biology and biochemistry from the University of Pittsburgh School of Medicine, an MBA from Carnegie Mellon University's Tepper School of Business and a BSc from the University of Notre Dame, Dr Hawryluk currently serves as the executive vice president and chief business officer of Gristone bio Inc, Predictive Oncology noted.
- 12/05/2022
|
Predictive Oncology Inc. (POAI) Q3 2022 Earnings Call Transcript
- Predictive Oncology Inc. (NASDAQ:POAI ) Q3 2022 Earnings Conference Call November 11, 2022 12:00 PM ET Company Participants Theresa Ferguson - Investor Relations Raymond Vennare - Chairman and Chief Executive Officer Pamela Bush - Senior Vice President of Strategic Sales and Business Development Bob Myers - Chief Financial Officer and Site Leader, Skyline Medical Conference Call Participants Michael Broadbent - Bedrock Group Inc. Operator Good day, ladies and gentlemen, and thank you for standing by. Welcome to the Predictive Oncology Third Quarter 2022 Earnings Conference Call.
- 11/11/2022
|
Predictive Oncology reports 45% revenue jump, increased gross profit margin in 3Q
- Predictive Oncology Inc. (NASDAQ:POAI) has reported revenue growth and an increased gross profit margin in its third quarter as the company continues to gain traction with potential partners with its breakthrough solution at a pivotal time in drug discovery. The company said during the quarter it leveraged its novel artificial intelligence-powered platform paired with the largest privately held biobank of over 150,000 tumor samples to help drug developers make higher confidence predictions of which molecules will and won't be successful, and ultimately leading to greater chances of commercial success.
- 11/11/2022
|
Predictive Oncology strengthens board of directors with life sciences and corporate attorney David Smith
- Predictive Oncology Inc. (NASDAQ:POAI) is beefing up its board with the appointment of David Smith, a life sciences and corporate attorney, veteran biotech industry executive and leading authority on the legal issues surrounding the therapeutic use of human tissue and cells. In a statement, the Minnesota-based biotech company cited Smith's “extensive transactional experience, venture financings and regulatory matters” for life sciences companies and investors.
- 10/25/2022
|
Predictive Oncology appoints biotech veteran Raymond Vennare as its new CEO and chairman
- Predictive Oncology Inc has announced the appointment of Raymond Vennare as the company's new CEO and board chairman, effective November 1, 2022. The company said Vennare, an active member of the Predictive Oncology board of directors since September 2021, will continue to work closely with senior management to expand its portfolio of proprietary solutions to advance the pipeline of drug development in oncology, ranging from early discovery through clinical trials.
- 10/20/2022
|
Predictive Oncology strengthens pharmaceutical and biotech offering; announces retirement of CEO and chairman J Melville Engle
- Predictive Oncology Inc. (NASDAQ:POAI) said it has further strengthened its offerings for pharmaceutical and biotech customers through several key developments. The company said the first was its Good Manufacturing Practices (GMP) lab, which opens the opportunity to help clients move from pre-clinical drug development to the investigational new drug (IND) qualification, including Phase 1 clinical trials.
- 09/19/2022
|
Predictive Oncology announces retirement of its chief executive officer and chairman, J. Melville Engle
- Predictive Oncology Inc. (NASDAQ:POAI) has announced that J. Melville (Mel) Engle will retire as its chief executive officer, chairman and a member of the company's board of directors.
- 09/19/2022
|
Predictive Oncology ends 2Q 2022 with strong balance sheet and solid cash position
- Predictive Oncology Inc. (NASDAQ:POAI) said it ended the second quarter of 2022 with a strong balance sheet, a solid cash position, commensurate equity, and no debt. The Minnesota-based company recognized net sales revenue of $400,000 for the three months ended June 30, 2022, an increase of 6% from the year-ago period, mainly due to a $100,000 sales contribution from its zPREDICTA subsidiary which is pioneering tumor-specific 3D cell culture services for anti-cancer drug testing.
- 08/12/2022
|
Predictive Oncology appoints Julia Kirshner as its new Chief Scientific Officer
- Predictive Oncology Inc. (NASDAQ:POAI) announced it has appointed Julia Kirshner to the newly-created role of Chief Scientific Officer (CSO). Kirshner, who up until now served as senior vice president at Predictive Oncology and president of its zPREDICTA division, will assume the role on August 1.
- 07/26/2022
|
Predictive Oncology closes two concurrent offerings raising gross proceeds of $7.2M
- Predictive Oncology Inc. (NASDAQ:POAI) said it has closed two concurrent offerings with several institutional investors, raising gross proceeds of approximately $7.2 million before placement agent fees and other offerings expenses. The company intends to use the net proceeds from the offerings for working capital purposes.
- 05/19/2022
|
Predictive Oncology to raise $7.2M in multiple offerings
- Predictive Oncology Inc has entered into definitive agreements to sell shares and units with multiple institutional investors that are expected to generate gross proceeds of $7.2 million, the company announced. In the first offering, the company will issue and sell more than 3.8 million shares at a price of $0.60 per share to several institutional investors for gross proceeds of $2.3 million.
- 05/16/2022
|
Predictive Oncology reports sharply higher consolidated revenue in 1Q 2022
- Predictive Oncology Inc saw its consolidated revenue for the first quarter ended March 31, 2022, rise to $314,568, up from the $280,317 it recorded in the corresponding quarter of 2021, which it believes points to "solid potential for growth in the upcoming period." The increase was driven by a 6% gain in the Skyline segment (STREAMWAY System product sales) and initial revenue from the zPREDICTA segment, the company said, adding that the zPREDICTA segment has an encouraging sales pipeline, including additional revenue from current transactions that are expected to be recognized in the next several quarters.
- 05/13/2022
|
Predictive Oncology has an AI-driven drug discovery platform to improve cancer treatments and speed up drug development
- Predictive Oncology Inc is blazing a path as a company that can operate through the fullness of the R&D spectrum of pharma and speed up new cancer treatments. The Minneapolis, Minnesota-based company shared initial results in December 2021, showing that its flagship drug discovery platform powered by both artificial intelligence (AI) and large patient datasets, can predict cancer drug responses with great accuracy.
- 05/10/2022
|
Predictive Oncology announces Theresa Ferguson as the company's senior director of Marketing
- Predictive Oncology Inc has announced that Theresa Ferguson has been named the company's senior director of Marketing. As Predictive Oncology's senior marketing leader, the company noted, Ferguson steps in as the company begins commercialization of its knowledge-driven technologies, applying artificial intelligence (AI) to develop personalized cancer therapies and improve patient outcomes.
- 04/26/2022
|
Predictive Oncology strengthens balance sheet in 2021; zPREDICTA acquisition highlights financial year
- Predictive Oncology Inc. (NASDAQ:POAI) has reported its financial results for 2021, a year which saw the company strengthen its balance sheet, acquire zPREDICTA Inc, and expand its sales and business development. The Minneapolis, Minnesota-based company, which is focused on applying AI to develop personalized cancer therapies, showed earlier this year via its proof-of-concept campaign that its Patient-centric Discovery by Active Learning (PeDal) platform could make high-confidence predictions of drug responses on ovarian tumor samples.
- 04/01/2022
|
HC Wainwright reiterates ‘Buy' rating on Predictive Oncology and $5 price target
- Analysts at HC Wainwright repeated their 'Buy' rating on Predictive Oncology Inc and $5 price target, noting that the company's artificial intelligence (AI) platform has executed “important early steps” and demonstrated “promising predictive capability". Minneapolis, Minnesota-based Predictive Oncology's subsidiary Helomics announced initial results in August last year showing that its AI-driven models of genomic data can predict cancer outcomes.
- 01/25/2022
|
7 of the Best Penny Stocks Under $3 for 2022 to Buy Now
- Penny stocks under $3 are full of potential and potential pitfalls. These are relatively safe and worth your consideration.
- 12/31/2021
|
Predictive Oncology Inc. (POAI) Upgraded to Buy: What Does It Mean for the Stock?
- Predictive Oncology Inc. (POAI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- 12/22/2021
|
Predictive Oncology Inc. (POAI) Reports Q3 Loss, Misses Revenue Estimates
- Predictive Oncology Inc. (POAI) delivered earnings and revenue surprises of 20.00% and -82.56%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
- 11/10/2021
|
Predictive Oncology Inc. (POAI) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
- Predictive Oncology Inc. (POAI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 11/08/2021
|
Predictive Oncology Launches Website Highlighting AI-Powered Cancer Research Advancements
- Predictive Oncology is leveraging AI to streamline drug discovery and development, improve outcomes in clinical testing and forge a new frontier of cancer research Predictive Oncology is leveraging AI to streamline drug discovery and development, improve outcomes in clinical testing and forge a new frontier of cancer research
- 10/19/2021
|
Are Penny Stocks Worth Buying? Check These 3 Out Right Now
- Three penny stocks that you should know about in October 2021 The post Are Penny Stocks Worth Buying? Check These 3 Out Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 09/30/2021
|
Hot Penny Stocks to Watch In the Last Week of September
- Making a list of penny stocks to buy next month? Check these three out The post Hot Penny Stocks to Watch In the Last Week of September appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 09/27/2021
|
Do These Penny Stocks Deserve a Place On Your Watchlist?
- Why investors are watching these penny stocks right now The post Do These Penny Stocks Deserve a Place On Your Watchlist? appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 09/22/2021
|
Predictive Oncology Reports Financial Results for Quarter Ended June 30, 2021, and Provides Business Update
- MINNEAPOLIS, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today reported financial results for the quarter ended June 30, 2021, and provided an update on business activities.
- 08/11/2021
|
Predictive Oncology Adjourns Special Meeting of Stockholders
- MINNEAPOLIS, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced today that the Company's Special Meeting of Stockholders, which was convened at 3:00 p.m. Central Time on August 10, 2021, has been adjourned for the purpose of soliciting more votes on the proposal to approve an amendment to the Company's certificate of incorporation to increase the number of authorized shares of Company common stock from 100,000,000 to 200,000,000 (the “Charter Proposal”). The Special Meeting has been scheduled to reconvene on August 17, 2021 at 3:00 p.m. Central time at the offices of Maslon LLP, 3300 Wells Fargo Center, 90 South Seventh Street, Minneapolis, MN 55402.
- 08/11/2021
|
Predictive Oncology subsidiary, Helomics uses data from the 100,000 Genomes Project to better predict ovarian cancer outcomes
- Initial results demonstrate that AI models of genomic data can predict cancer outcomes. This has the potential to help personalize ovarian cancer treatments and drive the discovery of new therapies. Initial results demonstrate that AI models of genomic data can predict cancer outcomes. This has the potential to help personalize ovarian cancer treatments and drive the discovery of new therapies.
- 08/03/2021
|
POAI Stock Price Increased 25.96%: Why It Happened
- The stock price of Predictive Oncology Inc (NASDAQ: POAI) increased by 25.96% yesterday. This is why it happened.
- 07/01/2021
|
Best Penny Stocks For Your July 2021 List? 8 Biotechs To Watch Now
- Current & former penny stocks to watch if you like biotech right now. The post Best Penny Stocks For Your July 2021 List?
- 06/30/2021
|
Hot Penny Stocks to Buy to Avoid Inflation? 7 For Your July Watchlist
- Which penny stocks are investors watching with inflation on the rise? Here's 7 for your list The post Hot Penny Stocks to Buy to Avoid Inflation?
- 06/30/2021
|
Predictive Oncology Inc.'s Subsidiaries Soluble Biotech Inc. and TumorGenesis Inc. are both constructing new GMP labs
- MINNEAPOLIS, June 22, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI), an AI-driven oncology and drug discovery company, announced today that two of their wholly owned subsidiaries, Soluble Biotech Inc. and TumorGenesis Inc. are both expanding their unique services by completing the fabrication and qualification of GMP facilities.
- 06/22/2021
|
Hot Penny Stocks to Buy Right Now? 7 For Your Watchlist
- Making a penny stocks watchlist for July? Check these 7 out The post Hot Penny Stocks to Buy Right Now?
- 06/18/2021
|
Predictive Oncology Announces Closing of $21.34 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
- MINNEAPOLIS, June 18, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced that it has completed the closing of its previously announced registered direct offering of 15,520,911 shares of its common stock and warrants to purchase up to an aggregate of 15,520,911 shares of its common stock at a purchase price of $1.375 per share of common stock and related warrant in a registered direct offering priced at-the-market under Nasdaq rules. The warrants have an exercise price of $1.25 per share, will become exercisable upon the Company increasing its authorized capital stock to 200 million shares, and will expire three (3) years following the date the warrants first become exercisable.
- 06/18/2021
|
Best Penny Stocks to Buy on Robinhood? 3 For Your Morning Watchlist
- Are these Robinhood penny stocks the best to watch in 2021? The post Best Penny Stocks to Buy on Robinhood?
- 06/17/2021
|
Best Biotech Penny Stocks to Buy? Here's 3 That Are Well Funded
- Looking for well-funded biotech penny stocks? Check these 3 small-caps out The post Best Biotech Penny Stocks to Buy?
- 06/16/2021
|
Predictive Oncology Announces $21.34 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
- MINNEAPOLIS, June 14, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that it has entered into definitive agreements with several institutional investors for the issuance and sale of an aggregate of 15,520,911 shares of its common stock and warrants to purchase up to an aggregate of 15,520,911 shares of its common stock at a purchase price of $1.375 per share of common stock and related warrant in a registered direct offering priced at-the-market under Nasdaq rules. The warrants have an exercise price of $1.25 per share, will become exercisable upon the Company increasing its authorized capital stock to 200 million shares, and will expire three (3) years following the date the warrants first become exercisable. The closing of the offering is expected to occur on or about June 15, 2021, subject to the satisfaction of customary closing conditions.
- 06/14/2021
|
Predictive Oncology Reports Financial Results for Quarter Ended March 31, 2021 and Provides Business Update
- MINNEAPOLIS, May 12, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (Nasdaq: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today reported financial results for the quarter ended March 31, 2021 and provided an update on business activities.
- 05/12/2021
|
Predictive Oncology Inc. Announces Newest Board Member
- MINNEAPOLIS, April 27, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, is excited to announce today their newest Board Member Dr. Christina Jenkins.
- 04/27/2021
|
Predictive Oncology Reports Year End 2020 Financial Results, Provides Business Update
- MINNEAPOLIS, March 15, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI) – Predictive Oncology (Nasdaq: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today reported financial results for the year ended December 31, 2020 and provided an update on business activities.
- 03/15/2021
|
Predictive Oncology: Potentially Undervalued Drug Discovery AI Company
- There is growing demand for AI use in drug development. Drug development deals go from $5 million to over $1 billion.
- 02/24/2021
|
POAI ‘s Helomics Division Announces Progress on Milestones for its AI-Driven Model of Ovarian Cancer
- Helomics Researchers Complete Key Sequencing Milestones and Focus on AI-Driven Model Building Helomics Researchers Complete Key Sequencing Milestones and Focus on AI-Driven Model Building
- 02/24/2021
|
Predictive Oncology Announces Closing of $17.6 Million Private Placement Priced At-the-Market
- MINNEAPOLIS, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced the closing of its previously announced private placement of common stock and warrants priced at-the-market under Nasdaq rules, resulting in gross proceeds to the Company of $17,635,343.70. The Company sold and issued an aggregate of 9,043,766 shares of its common stock and warrants to purchase up to an aggregate of 4,521,883 shares of common stock in the private placement, at a purchase price of $1.95 per share of common stock and associated warrant. The warrants have an exercise price of $2.00 per share, are exercisable immediately and have a term of five and one-half years.
- 02/23/2021
|
Two Top Researchers find Breakthrough Discoveries using Predictive Oncology's Wholly Owned Subsidiary, TumorGenesis's Technology
- MINNEAPOLIS, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced today that the products of its wholly owned subsidiary, TumorGenesis, aided researchers in the understanding of how ovarian cancer cells migrate outside the abdominal cavity. The research, completed by a top-tier laboratory in Massachusetts, used TumorGenesis's media to capture, culture, and identify how these cells ‘break through' the protective lining in the abdomen, called the omentum or abdominal membrane.
- 02/17/2021
|
Predictive Oncology Announces Closing of $7.4 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
- MINNEAPOLIS, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced the closing of its previously announced registered direct offering of 4,222,288 shares of its common stock, at a purchase price of $1.75 per share, which was priced at-the-market under Nasdaq rules. The gross proceeds to the Company from this offering were approximately $7.4 million, before deducting the placement agent's fees and other offering expenses payable by the Company. In a concurrent private placement, the Company also issued to the same investors unregistered warrants to purchase up to an aggregate of 2,111,144 shares of common stock at an exercise price of $2.00 per share. The warrants are exercisable immediately upon issuance and have a term and five and one-half years.
- 02/16/2021
|
Predictive Oncology Announces $7.4 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
- MINNEAPOLIS, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that it has entered into definitive agreements with several institutional and accredited investors for the issuance and sale of an aggregate of approximately 4,222,288 shares of its common stock, at a purchase price of $1.75 per share, for gross proceeds of approximately $7.4 million in a registered direct offering priced at-the-market under Nasdaq rules. Predictive Oncology has also agreed to issue to the investors unregistered warrants to purchase up to an aggregate of approximately 2,111,114 shares of common stock. The closing of the offering is expected to occur on or about February 16, 2021, subject to the satisfaction of customary closing conditions.
- 02/11/2021
|
Predictive Oncology's Wholly Owned Subsidiary Helomics announces the start of its drug repurposing project using its ground-breaking PeDAL™ platform for ovarian cancer
- MINNEAPOLIS, Feb. 08, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced today that it will start an in-house drug repurposing project, focused on ovarian cancer, using its proprietary AI-driven, patient centric discovery platform – PeDAL™. The project will use PeDAL to rapidly and cost-effectively profile panel of existing drugs against hundreds of patient cell lines. This process will generate data on which compounds are active against which specific patient profile(s), delivering both proof data for the PeDAL approach and valuable Intellectual Property (IP) for the company.
- 02/08/2021
|
Predictive Oncology Has Regained Compliance with Nasdaq's Minimum Bid Price Requirement
- MINNEAPOLIS, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that based on a notification letter recently received from the Listing Qualifications Department of the Nasdaq Stock Market Inc. (the “Nasdaq”), the Company has regained compliance with the minimum bid price requirement set forth in Rule 5550(a)(2) of the Nasdaq Listing Rules (the “Minimum Bid Price Requirement”).
- 02/02/2021
|
Predictive Oncology Announces Closing of $4.1 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
- MINNEAPOLIS, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced the closing of its previously announced registered direct offering of 3,414,970 shares of its common stock, at a purchase price of $1.20 per share, which was priced at-the-market under Nasdaq rules. The gross proceeds to the Company from this offering were approximately $4.1 million, before deducting the placement agent's fees and other offering expenses payable by the Company. In a concurrent private placement, the Company also issued to the same investors unregistered warrants to purchase up to an aggregate of 1,707,485 shares of common stock at an exercise price of $1.37 per share. The warrants are exercisable immediately upon issuance and have a term and five and one-half years.
- 01/26/2021
|
Predictive Oncology Announces $4.1 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
- MINNEAPOLIS, Jan. 22, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that it has entered into definitive agreements with several institutional and accredited investors for the issuance and sale of an aggregate of approximately 3,414,970 shares of its common stock, at a purchase price of $1.20 per share, for gross proceeds of approximately $4.1 million in a registered direct offering priced at-the-market under Nasdaq rules. Predictive Oncology has also agreed to issue to the investors unregistered warrants to purchase up to an aggregate of approximately 1,707,485 shares of common stock. The closing of the offering is expected to occur on or about January 26, 2021, subject to the satisfaction of customary closing conditions.
- 01/22/2021
|
Predictive Oncology Announces Closing of $2.2 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
- MINNEAPOLIS, Jan. 21, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced the closing of its previously announced registered direct offering of 2,200,000 shares of its common stock, at a purchase price of $1.00 per share, which was priced at-the-market under Nasdaq rules. The gross proceeds to the Company from this offering were $2.2 million, before deducting the placement agent's fees and other offering expenses payable by the Company. In a concurrent private placement, the Company also issued to the same investors unregistered warrants to purchase up to an aggregate of 1,100,000 shares of common stock at an exercise price of $1.00 per share. The warrants are exercisable immediately upon issuance and have a term and five and one-half years.
- 01/21/2021
|
Predictive Oncology Reports That Its Wholly Owned Subsidiary, TumorGenesis, Has Sold Media to Two Top Research Medical Centers
- EAGAN, Minn., Jan. 14, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced today that its wholly owned subsidiary TumorGenesis, Inc. in the last quarter has sold media to two top research medical centers, one in New York City and the other in Boston, Massachusetts. Both the New York City and the Boston orders are repeat orders and are focused on culturing ovarian cancer cells with specific research goals. One additional order came from a private company doing research on ovarian cancer.
- 01/14/2021
|
Predictive Oncology Announces Closing of $3.074 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
- MINNEAPOLIS, Jan. 12, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced the closing of its previously announced registered direct offering of 3,650,840 shares of its common stock, at a purchase price of $0.842 per share, which was priced at-the-market under Nasdaq rules. The gross proceeds to the Company from this offering were $3.074 million, before deducting the placement agent's fees and other offering expenses payable by the Company. In a concurrent private placement, the Company also issued to the same investors unregistered warrants to purchase up to an aggregate of 1,825,420 shares of common stock at an exercise price of $0.80 per share.
- 01/12/2021
|
Predictive Oncology Announces $3,074,007 Registered Direct Offering Priced At-The-Market under Nasdaq Rules
- MINNEAPOLIS, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that it has entered into definitive agreements with several institutional and accredited investors for the issuance and sale of an aggregate of 3,650,840 shares of its common stock, at a purchase price of $0.842 per share, for gross proceeds of approximately $3.0 million in a registered direct offering priced at-the-market under Nasdaq rules. Predictive Oncology has also agreed to issue to the investors unregistered warrants to purchase an aggregate of up to 1,825,420 shares of common stock. The closing of the offering is expected to occur on or about January 12, 2021, subject to the satisfaction of customary closing conditions.
- 01/08/2021
|
Predictive Oncology's Wholly Owned Subsidiary Helomics completes integration of Quantitative Medicine
- Our new PeDAL fee-for-service offering for Pharmaceutical companies will significantly improve the chances of translating discoveries into the clinic Our new PeDAL fee-for-service offering for Pharmaceutical companies will significantly improve the chances of translating discoveries into the clinic
- 01/06/2021
|
Predictive Oncology Hires Investor Relations Firm
- MINNEAPOLIS, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, is pleased to announce that it has engaged Landon Capital to provide investor relations services effective December 30, 2020. Services will include introductions to investors, financial and industry analysts, registered brokers and financial writers with a view to informing such groups about developments in the Company's business and affairs. Landon Capital will assist to develop a database of individuals, financial institutions or other persons potentially interested in receiving publicly available information relating to the Company and making efforts to efficiently provide such information.
- 01/05/2021
|
Predictive Oncology Announces Cancellation of Special Meeting in December 2020
- Reincorporation Proposal Received Overwhelming Support Among Shares Voted Reincorporation Proposal Received Overwhelming Support Among Shares Voted
- 12/29/2020
|
Predictive Oncology Sends Letter to Shareholders Regarding Special Meeting to be Reconvened on December 30, 2020
- NEW YORK, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today sent a letter to shareholders regarding its virtual Special Meeting of Stockholders, original scheduled for December 1, 2020, which will be reconvened December 30, 2020 at 3 p.m. CST.
- 12/09/2020
|
Predictive Oncology Reports Third Quarter 2020 Financial Results, Provides Business Update
- NEW YORK, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today reported financial results for the quarter ended September 30, 2020 and provided a business update.
- 11/16/2020
|
Predictive Oncology Inc. CEO Provides Updates on Subsidiaries, Highlights Recent Milestones and Near-Term Goals
- NEW YORK, Oct. 27, 2020 (GLOBE NEWSWIRE) -- via NetworkNewsAudio — Predictive Oncology Inc. (NASDA Q : POAI) today announces that its chief executive officer, Carl Schwartz, has been featured in an exclusive audio interview with NetworkNewsWire (“NNW”), a financial news and content distribution company and one of 50+ brands in the InvestorBrandNetwork (“IBN”). During the interview, Schwartz provided an update on the company's recent milestones and near-term goals following the October release of his Letter t o Shareholders. In particular, Schwartz put a focus on the company's subsidiaries: Skyline Medical, TumorGenesis, Soluble Biotech and Helomics.
- 10/27/2020
|
